{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T05:52:06Z","timestamp":1768369926684,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bronchiectasis is a chronic pulmonary disease characterized by pathological bronchial enlargement due to various underlying etiologies, leading to symptoms such as chronic cough, sputum production, and recurrent respiratory infections. However, the impact of comorbid bronchiectasis on the clinical course of lung cancer remains unclear. This study aims to evaluate the role of bronchiectasis as a comorbidity and complication in patients with lung cancer, specifically in relation to survival, the incidence of pneumonia and healthcare costs. In this retrospective analysis, we utilized claims data from 36,272 German lung cancer patients. Patients with and without comorbid bronchiectasis were matched using propensity score matching (1:1). The minimum follow-up period for all patients was three years. Survival differences were assessed using Kaplan-Meier curves and the Log-Rank test. The occurrence of pneumonia was analyzed using absolute and relative frequencies and compared with a McNemar test for paired samples. To compare costs between the matched groups, we used means with standard deviation and paired t-tests. A total of 572 patients (1.6%) had bronchiectasis, of these, 63.6% were diagnosed prior to lung cancer (PRE bronchiectasis), while 36.4% received the diagnosis thereafter (POST bronchiectasis). No significant difference in survival was observed in the PRE cohort, while the risk for death was significantly higher in bronchiectasis patients in the POST cohort compared to controls (HR\u2009=\u20092.22; 95% CI 1.71\u20132.87;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Among patients undergoing systemic therapy or radiotherapy, patients with bronchiectasis developed pneumonia more often during follow-up, compared patients without bronchiectasis (PRE: 62.4% vs. 45.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001; POST: 64.9% vs. 44.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Total costs, as well as expenses for inpatient hospital treatment, doctor visits, and medications, were significantly higher in patients with bronchiectasis. However, after adjusting for survival time, these differences were no longer significant. Pre-existing bronchiectasis does not appear to adversely affect survival in patients with lung cancer. In contrast, incident bronchiectasis developing during follow-up is associated with significantly worse outcomes. Clinically, patients with bronchiectasis should be monitored closely for infectious complications, particularly pneumonia.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-34656-2","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:53:24Z","timestamp":1767988404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of bronchiectasis in lung cancer using German claims data"],"prefix":"10.1038","volume":"16","author":[{"given":"Jeremias","family":"G\u00f6tschke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Kahnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"G\u00f6tschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore S.","family":"Kapellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pontus","family":"Mertsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"3","key":"34656_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"34656_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cllc.2023.06.011","volume":"24","author":"MZ Guo","year":"2023","unstructured":"Guo, M. Z. et al. Infectious complications in patients with Non-small cell lung cancer treated with immune checkpoint inhibitors. Clin. Lung Cancer. 24 (7), 613\u2013620 (2023).","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"34656_CR3","first-page":"8","volume":"17","author":"KS Akinosoglou","year":"2013","unstructured":"Akinosoglou, K. S., Karkoulias, K. & Marangos, M. Infectious complications in patients with lung cancer. Eur. Rev. Med. Pharmacol. Sci. 17 (1), 8\u201318 (2013).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"34656_CR4","doi-asserted-by":"crossref","unstructured":"Ringshausen, F. C. et al. Increasing bronchiectasis prevalence in Germany, 2009\u20132017: a population-based cohort study. Eur. Respir J. 54, 1900499 (2019).","DOI":"10.1183\/13993003.00499-2019"},{"issue":"9","key":"34656_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1513\/AnnalsATS.202111-1257OC","volume":"19","author":"H Choi","year":"2022","unstructured":"Choi, H. et al. Non-Cystic fibrosis bronchiectasis increases the risk of lung cancer independent of smoking status. Ann. Am. Thorac. Soc. 19 (9), 1551\u20131560 (2022).","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"3","key":"34656_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","volume":"10","author":"S Aliberti","year":"2022","unstructured":"Aliberti, S. et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 10 (3), 298\u2013306 (2022).","journal-title":"Lancet Respir Med."},{"issue":"1","key":"34656_CR7","first-page":"423","volume":"5","author":"D Qiao","year":"2015","unstructured":"Qiao, D. et al. A retrospective study of risk and prognostic factors in relation to lower respiratory tract infection in elderly lung cancer patients. Am. J. Cancer Res. 5 (1), 423\u2013432 (2015).","journal-title":"Am. J. Cancer Res."},{"key":"34656_CR8","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft & Krebshilfe, D. AWMF): S3-Leitlinie Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 3.0, 2024, AWMF-Registernummer: 020-007OL https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/lungenkarzinom\/; Zugriff am [17.01.2024]."},{"issue":"11","key":"34656_CR9","first-page":"1602","volume":"12","author":"S Finch","year":"2015","unstructured":"Finch, S., McDonnell, M. J., Abo-Leyah, H., Aliberti, S. & Chalmers, J. D. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 12 (11), 1602\u20131611 (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"1","key":"34656_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccc.2020.09.001","volume":"37","author":"SK Seo","year":"2021","unstructured":"Seo, S. K., Liu, C. & Dadwal, S. S. Infectious disease complications in patients with cancer. Crit. Care Clin. 37 (1), 69\u201384 (2021).","journal-title":"Crit. Care Clin."},{"issue":"1","key":"34656_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1378\/chest.124.1.114","volume":"124","author":"T Berghmans","year":"2003","unstructured":"Berghmans, T., Sculier, J. P. & Klastersky, J. A prospective study of infections in lung cancer patients admitted to the hospital. Chest 124 (1), 114\u2013120 (2003).","journal-title":"Chest"},{"issue":"7","key":"34656_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","volume":"11","author":"JD Chalmers","year":"2023","unstructured":"Chalmers, J. D. et al. Bronchiectasis in europe: data on disease characteristics from the European bronchiectasis registry (EMBARC). Lancet Respir Med. 11 (7), 637\u2013649 (2023).","journal-title":"Lancet Respir Med."},{"key":"34656_CR13","doi-asserted-by":"crossref","unstructured":"Blanchette, C. M. et al. Healthcare cost and utilization before and after diagnosis of Pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the U.S. Med. Sci.  5, 20 (2017).","DOI":"10.3390\/medsci5040020"},{"issue":"2","key":"34656_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00408-014-9675-5","volume":"193","author":"M Iachina","year":"2015","unstructured":"Iachina, M. et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung 193 (2), 291\u2013297 (2015).","journal-title":"Lung"},{"issue":"1","key":"34656_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejcts.2004.09.010","volume":"27","author":"A Lopez-Encuentra","year":"2005","unstructured":"Lopez-Encuentra, A. et al. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur. J. Cardiothorac. Surg. 27 (1), 8\u201313 (2005).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"34656_CR16","unstructured":"AOK Bundesverband. Zahlen und Fakten (2015)."},{"issue":"2","key":"34656_CR17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart, E. et al. [Good practice of secondary data analysis (GPS): guidelines and recommendations]. Gesundheitswesen 77 (2), 120\u2013126 (2015).","journal-title":"Gesundheitswesen"},{"key":"34656_CR18","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria 2016. (2016)."},{"issue":"1","key":"34656_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1164\/rccm.202309-1614OC","volume":"210","author":"E Polverino","year":"2024","unstructured":"Polverino, E. et al. The association between bronchiectasis and chronic obstructive pulmonary disease: data from the European bronchiectasis registry (EMBARC). Am. J. Respir Crit. Care Med. 210 (1), 119\u2013127 (2024).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"10","key":"34656_CR20","doi-asserted-by":"publisher","first-page":"e021611","DOI":"10.1136\/bmjopen-2018-021611","volume":"8","author":"LM O\u2019Keeffe","year":"2018","unstructured":"O\u2019Keeffe, L. M. et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 8 (10), e021611 (2018).","journal-title":"BMJ Open."},{"issue":"12","key":"34656_CR21","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/IAI.00501-09","volume":"77","author":"AY Koh","year":"2009","unstructured":"Koh, A. Y., Priebe, G. P., Ray, C., Van Rooijen, N. & Pier, G. B. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect. Immun. 77 (12), 5300\u20135310 (2009).","journal-title":"Infect. Immun."},{"issue":"3","key":"34656_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/07357907.2013.767342","volume":"31","author":"JL Campian","year":"2013","unstructured":"Campian, J. L., Ye, X., Brock, M. & Grossman, S. A. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest. 31 (3), 183\u2013188 (2013).","journal-title":"Cancer Invest."},{"issue":"2","key":"34656_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","volume":"105","author":"CJ Ladbury","year":"2019","unstructured":"Ladbury, C. J., Rusthoven, C. G., Camidge, D. R., Kavanagh, B. D. & Nath, S. K. Impact of radiation dose to the host immune system on tumor control and survival for stage III Non-Small cell lung cancer treated with definitive radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 105 (2), 346\u2013355 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10150","key":"34656_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume, P. A., Chalmers, J. D. & Olivier, K. N. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet 392 (10150), 880\u2013890 (2018).","journal-title":"Lancet"},{"issue":"3","key":"34656_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.chest.2017.06.042","volume":"152","author":"LW Chen","year":"2017","unstructured":"Chen, L. W. et al. De Novo development of bronchiectasis in patients with hematologic malignancy. Chest 152 (3), 683\u2013685 (2017).","journal-title":"Chest"},{"key":"34656_CR26","doi-asserted-by":"crossref","unstructured":"Quellhorst, L. et al. Psychometric validation of the German translation of the quality of life Questionnaire-Bronchiectasis (QOL-B)-Data from the German bronchiectasis registry PROGNOSIS. J. Clin. Med. 11, 441 (2022).","DOI":"10.3390\/jcm11020441"},{"issue":"5","key":"34656_CR27","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.21037\/jtd.2020.04.49","volume":"12","author":"AJ Patel","year":"2020","unstructured":"Patel, A. J. et al. Characterising the impact of pneumonia on outcome in non-small cell lung cancer: identifying preventative strategies. J. Thorac. Dis. 12 (5), 2236\u20132246 (2020).","journal-title":"J. Thorac. Dis."},{"issue":"5","key":"34656_CR28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/JTO.0b013e3181d2dcd9","volume":"5","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi, T. et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J. Thorac. Oncol. 5 (5), 620\u2013630 (2010).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"34656_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12890-020-1160-8","volume":"20","author":"JW Heo","year":"2020","unstructured":"Heo, J. W. et al. Smoking is associated with pneumonia development in lung cancer patients. BMC Pulm Med. 20 (1), 117 (2020).","journal-title":"BMC Pulm Med."},{"key":"34656_CR30","doi-asserted-by":"publisher","first-page":"1610109","DOI":"10.3389\/pore.2022.1610109","volume":"28","author":"CL Zhang","year":"2022","unstructured":"Zhang, C. L., Fan, K., Gao, M. Q. & Pang, B. Prognostic value of Glasgow prognostic score in Non-small cell lung cancer: A systematic review and Meta-Analysis. Pathol. Oncol. Res. 28, 1610109 (2022).","journal-title":"Pathol. Oncol. Res."},{"issue":"9","key":"34656_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1159\/000488688","volume":"41","author":"D Kauffmann-Guerrero","year":"2018","unstructured":"Kauffmann-Guerrero, D., Kahnert, K., Syunyaeva, Z., Tufman, A. & Huber, R. M. Pretherapeutic inflammation predicts febrile neutropenia and reduced Progression-Free survival after First-Line chemotherapy in SCLC. Oncol. Res. Treat. 41 (9), 506\u2013512 (2018).","journal-title":"Oncol. Res. Treat."},{"key":"34656_CR32","doi-asserted-by":"crossref","unstructured":"Diel, R. et al. Economic burden of bronchiectasis in Germany. Eur. Respir J. 53, 1802033 (2019).","DOI":"10.1183\/13993003.02033-2018"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34656-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34656-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34656-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:04:00Z","timestamp":1768345440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34656-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34656"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34656-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1619"}}